Pineal parenchymal tumor of intermediate differentiation
disease diseaseOn this page
Also known as pineal parenchymal tumor of intermediate differentiation (morphologic abnormality)pineal parenchymal tumors of intermediate differentiationpineal parenchymal tumour of intermediate differentiation (morphologic abnormality)pineal parenchymal tumours of intermediate differentiationPPTID
Summary
Pineal parenchymal tumor of intermediate differentiation (MONDO:0006369) is a cancer and 1 clinical trial. Top therapeutic interventions include filgrastim and sonidegib. A subtype of pineal parenchymal cell neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 1
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | pineal parenchymal tumor of intermediate differentiation |
| Mondo ID | MONDO:0006369 |
| EFO | EFO:1000474 |
| Orphanet | 251919 |
| DOID | DOID:5030 |
| NCIT | C6967 |
| SNOMED CT | 715904005 |
| UMLS | C1367859 |
| MedGen | 234566 |
| GARD | 0010644 |
| Is cancer (heuristic) | yes |
Also known as: pineal parenchymal tumor of intermediate differentiation · pineal parenchymal tumor of intermediate differentiation (morphologic abnormality) · pineal parenchymal tumors of intermediate differentiation · pineal parenchymal tumour of intermediate differentiation (morphologic abnormality) · pineal parenchymal tumours of intermediate differentiation · PPTID
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › nervous system neoplasm › neuroepithelial neoplasm › pineal parenchymal cell neoplasm › pineal parenchymal tumor of intermediate differentiation
Related subtypes (2): adult pineal parenchymal tumor, pineocytoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 1.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03434262 | PHASE1 | COMPLETED | SJDAWN: St. Jude Children’s Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FILGRASTIM | 4 | 1 |
| SONIDEGIB | 4 | 1 |
Related Atlas pages
- Drugs: Filgrastim, Sonidegib